ZYBERNO
Stock Report
Updated Sep 1, 2026

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Healthcare • OTC

$0.06

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-1,307.7%)
Return on Capital (Capital Efficiency):CRITICAL (-1,085.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.06
Market Cap:$23.76M

Valuation Multiples (2)

P/S Ratio:67.81x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$26.80M

Price Action & Momentum (3)

Momentum Percentile:30 / 100
% of 52-Week High:62.8%
B. Profitability Assessment

Return Metrics (4)

ROA:-599.6%
Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.6%

Margin Analysis (3)

Operating Margin Ttm:-1,307.7%
Net Margin Ttm:-1,355.3%
Ebitda Margin:-1,307.2%

TTM Performance (2)

Operating Margin Ttm:-1,307.7%
Net Margin Ttm:-1,355.3%

Yield Metrics (2)

Earnings Yield:-$17.86
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-100.0%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-32.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.18x
Quick Ratio:0.18x
Cash Ratio:0.15x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-660.20x
Times Interest Earned:-660.20

Capital Structure (4)

Working Capital:-6,338,261.00
Cash And Cash Equivalents:1,156,915.00
Long Term Debt:$53.92K
Net Debt:$3.04M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $350.44K
Linear Growth: -32.6%
📊 Click to view full PVCT Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$4.58M

Bottom Line Performance (3)

-$4.75M
Income Before Tax:-$5.51M
Ebitda Ttm:-4,580,815.00

Operating Expenses (5)

Operating Expenses:4,582,677.00
R And D Expense:1,105,585.00
Sga Expense:3,477,092.00
Income Tax Expense:$0.00
Interest Expense:8,020.00

Expense Ratios (1)

Ebitda Margin:-1,307.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.47M
Current Assets:$1.37M
Ppe Net:2,068.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,761,065.00
Current Liabilities:7,707,145.00
Long Term Debt:$53.92K
Short Term Debt:$4.14M

Equity & Capital (3)

Equity:-$6.29M
Retained Earnings:-$265.13M
Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:4,141,079.00

Special Items (2)

Contract Liabilities:57,480.00
Stock Based Compensation:305,944.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.59M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$329.87K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:75,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,862.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.01
-$0.01
Earnings Per Share Ttm:-$0.01

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.01

Book Value & Capital (2)

Book Value Per Share:-$0.01
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.44x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:4,313.13
Cash Conversion Cycle:-6,311.13
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-32.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:PVCT
Company Name:PROVECTUS BIOPHARMACEUTICALS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:420.28M
Shares Outstanding Basic:420.28M
Shares Outstanding Diluted:420.28M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 08:54:07 UTC
Data Timestamp:2026-08-20T22:24:17.122123
Scroll to Top